Novo Nordisk has filed a lawsuit against rival Eli Lilly, alleging that advertisements for its blockbuster weight-loss drugs contain misleading claims.
The Danish drugmaker argues that Eli Lilly compared its medicines with older doses of Novo Nordisk’s products, creating an unfair impression of superior effectiveness.
Novo Nordisk has asked the court to stop the advertisements and seek damages. Eli Lilly has defended its marketing, saying the claims are backed by scientific evidence and clinical trial data.
The legal battle highlights the fierce competition in the rapidly growing GLP-1, obesity drug and weight-loss treatment market.